Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults.
In an early-stage clinical trial led by the Dana-Farber Cancer Institute in Boston, a personalized vaccine prompted an anti-cancer immune response in all nine participants. These patients had been diagnosed with advanced disease and were given the vaccine after their tumors had been surgically removed. All remained cancer-free after a median follow-up period of just under three years. The trial results were published Feb. 5 in the journal Nature.
